BSX VS ZTS Stock Comparison

PerformanceAnalyst Price TargetsTechnicalsEarningsProfitVolatilityDividend
PerformanceAnalyst Price TargetsTechnicalsEarningsProfitVolatilityDividend

Performance

BSX
100/100

BSX returned 26.68% in the last 12 months. Based on SPY's performance of -12.97%, its performance is above average giving it a score of 100 of 100.

ZTS
100/100

ZTS returned 16.56% in the last 12 months. Based on SPY's performance of -13.45%, its performance is above average giving it a score of 100 of 100.

Analyst Price Targets

BSX
79/100

24 analysts offer 12-month price targets for BSX. Together, they have an average target of 57.93, the most optimistic target put BSX at 132 within 12-months and the most pessimistic has BSX at 43.

ZTS
75/100

21 analysts offer 12-month price targets for ZTS. Together, they have an average target of 0, the most optimistic target put ZTS at 0 within 12-months and the most pessimistic has ZTS at 0.

Technicals

BSX
89/100

BSX receives a 89 of 100 based on 14 indicators. 12 are bullish, 1 are bearish.

ZTS
82/100

ZTS receives a 82 of 100 based on 14 indicators. 11 are bullish, 2 are bearish.

Earnings

BSX
26/100

BSX has missed earnings 4 times in the last 20 quarters.

ZTS
53/100

ZTS has missed earnings 2 times in the last 20 quarters.

Profit

BSX
72/100

Out of the last 20 quarters, BSX has had 18 profitable quarters and has increased their profits year over year on 8 of them.

ZTS
78/100

Out of the last 20 quarters, ZTS has had 19 profitable quarters and has increased their profits year over year on 11 of them.

Volatility

BSX
48/100

BSX has had a lower than average amount of volatility over the last 12 months giving it a score of 47 of 100.

ZTS
50/100

ZTS has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.

Dividend

BSX
10/100

BSX's most recent dividend was $0.01 per share, based on a share price of $53.85. It was a payout ratio of -8.24% compared to their total earnings.

ZTS
35/100

ZTS's most recent dividend was $0.12 per share, based on a share price of $174.62. It was a payout ratio of 17.39% compared to their total earnings.

All score calculations are broken down here to help you make more informed investing decisions

Boston Scientific Corp. Summary

New York Stock Exchange / BSX
Healthcare
Medical - Devices
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

ZOETIS INC. Summary

New York Stock Exchange / ZTS
Healthcare
Drug Manufacturers - Specialty & Generic
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.